ImmunoOncology is a key pillar of our approach to advancing cancer research. We are following the science to more personalised treatments that may deliver improved outcomes for patients. CIM19pic.twitter.comLcgQXij7sO

#ImmunoOncology is a key pillar of our approach to advancing #cancer research. We are following the science to more personalised treatments that may deliver improved outcomes for patients. #CIM19pic.twitter.com/LcgQXij7sO

10:31 EDT 25 Jun 2019 | AztraZeneca

#ImmunoOncology is a key pillar of our approach to advancing #cancer research. We are following the science to more personalised treatments that may deliver improved outcomes for patients. #CIM19 pic.twitter.com/LcgQXij7sO

More From BioPortfolio on "#ImmunoOncology is a key pillar of our approach to advancing #cancer research. We are following the science to more personalised treatments that may deliver improved outcomes for patients. #CIM19pic.twitter.com/LcgQXij7sO"